BofA Securities Downgrades BioXcel Therapeutics (BTAI) to Underperform, 'The next 12 months will be a critical inflection point'
Tweet Send to a Friend
BofA Securities analyst Alec Stranahan downgraded BioXcel Therapeutics (NASDAQ: BTAI) from Neutral to Underperform with a price target of $0.25 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
